Physician profile
Leon Rovner
NPI 1811013766
$4,253.40
in general payments reported to CMS, 2019-2025
25 companies · $1,221 in 2025
The $1,221 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $49.95 · 2021: $75.08 · 2022: $526 · 2023: $509 · 2024: $1,672 · 2025: $1,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,798 · Consulting Fee: $500 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,798.24 |
| Consulting Fee | $500.00 |
| Education | $104.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gastroklenz, INC. Dba Cloudcath | $1,069.55 | 2022-2025 | |
| Akebia Therapeutics INC | $509.34 | 2021-2025 | Vafseo, Auryxia |
| Ardelyx, INC. | $359.13 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Alexion Pharmaceuticals, INC. | $293.51 | 2024 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $284.29 | 2022-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $224.07 | 2024-2025 | |
| Amgen INC. | $198.69 | 2019-2025 | Krystexxa, Tavneos |
| Aurinia Pharma U.S., INC. | $169.75 | 2023-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $163.34 | 2022-2025 | |
| Vertex Pharmaceuticals Incorporated | $125.00 | 2023 | |
| Genzyme Corporation | $120.85 | 2024 | |
| Vifor Pharma, INC. | $112.68 | 2020-2025 | Veltassa |
| Calliditas Therapeutics US INC. | $109.67 | 2023-2024 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $82.52 | 2019-2025 | Voyxact |
| Fresenius USA Marketing, INC. | $80.04 | 2019-2023 | Velphoro |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.32 | 2024-2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $51.78 | 2025 | Voyxact |
| Outset Medical INC | $47.59 | 2024 | |
| Opko Pharmaceuticals, LLC | $38.41 | 2024-2025 | Rayaldee |
| Travere Therapeutics, INC. | $34.07 | 2025 | |
| Mallinckrodt Hospital Products INC. | $29.38 | 2023 | Terlivaz |
| Horizon Therapeutics Plc | $27.25 | 2021 | |
| Scpharmaceuticals INC. | $26.44 | 2025 | |
| Boston Scientific Corporation | $19.35 | 2020 | |
| Novo Nordisk INC | $17.38 | 2025 | Rivfloza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Rovner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.